CB

Claire Bugos

Health News Reporter at Verywell Health

Claire Bugos is a New York-based health and science reporter and writer with a focus on public health and medicine. She joined Verywell Health as a staff reporter in 2021.

Her work appears in Smithsonian Magazine and Discover Magazine, where she's written on medical advancements, astronomy, the environment, archaeology, and art. As print managing editor for her college magazine, North by Northwestern, she led the creation of the publication's first-ever special section on the topic of environmentalism. She was a 2020 National Association of Science Writers travel fellow.

  • New York, New York, United States

Covers

Publications

  • Verywell Health
    3 articles
  • VeryWell Health
    1 article

Writes Most On

ExerciseObesityTreatmentClinicalTrialsTumorStagesZepboundCancerCellGrowthWeightLossPlateauSwedishStudySleephealthHungerControlMetabolichealthInflammationEarlyStageColorectalCancerDiabetesPreventionClinicalRecommendationsProphylaxisWeightLossUlcerativeColitisMedicalResearchPreventiveToolGLP1WeightLossDrugsOzempicSuperRespondersLifestylechangesIBDDiabetesCareStatinsGutHormonesCrohnsDiseaseBariatricSurgeryColorectalCancerRiskWegovyEquilibriumHealthBenefitsHeartHealthChemotherapyResistanceStressManagementBodyweightGlp1LeftSidedColonCancerCoMorbiditiesNewWeightLossMedicationsCholesterolImprovementObesityManagementMetabolicPathwayAntiInflammatoryPropertiesSemaglutideGIPCalorieDeficitWeightLossStrategies
  • Most Popular
  • Recent Work
  • Requests
  • 4 Reasons Weight Loss Drugs Aren't Working for You
    24 Apr 2024—VeryWell Health
    Key Takeaways Not everyone will see meaningful weight loss when taking Ozempic, Zepbound, or another GLP-1 based drug. Paying attention to lifestyle factors, like getting adequate exercise and eating well, can improve your outcomes on the medication. Adjusting your prescription or considering other weight management options could help, too. Many people who take GLP-1 receptor agonist drugs such as Wegovy (semaglutide) and Zepbound (tirzepatide) will lose significant weight and see multiple...
  • What Happens When You Stop Losing Weight on Drugs Like Ozempic or Wegovy?
    16 Feb 2024—Verywell Health
    Key Takeaways Most people who take GLP-1 weight loss drugs will stop dropping pounds between 9 and 12 months. A plateau does not mean the medication stopped working. Adhering to a healthy diet and getting enough exercise can help avoid muscle loss that can slow down weight loss and cause other health problems. New weight loss medications like Wegovy and Zepbound have been heralded as game changers for treating obesity. While these drugs don’t outperform bariatric surgery—the gold standard for...
  • Statins Can Cut Colorectal Cancer Risk in Ulcerative Colitis Patients, Study Finds
    20 Sep 2023—Verywell Health
    Key Takeaways A recent large study indicates that patients with ulcerative colitis who take statins are at a lower risk for developing and dying from colorectal cancer. The group on statins was also less likely to die from colorectal cancer or any cause. Decades of research suggest that statins could have anti-cancer effects. Cholesterol-lowering statins may have benefits beyond supporting heart health for people with ulcerative colitis, a type of inflammatory bowel disease (IBD). A recent...

People Also Viewed